Build-Up Phase: Weekly Allergen Injections Begin
Weekly injections introduce tiny allergen doses under the skin.
- 1×/week: Typical frequency (placeholder metric)
- Very low: Start dose (placeholder metric)
- 3–6 mo: Duration (placeholder metric)
- Clinic: Setting (placeholder metric)
Why start low and slow
Low starting doses limit reaction risk while priming immune response.
Dose Escalation Across Months
Each visit raises the allergen dose toward an effective target.
- ~4 mo: Escalation span (placeholder metric)
- Gradual: Dose increase (placeholder metric)
- 30 min: Observation (placeholder metric)
- Local/systemic: Reactions watched (placeholder metric)
Reaching the maintenance dose
Doses climb until the target maintenance concentration is reached.
Maintenance Phase: Monthly Injections
Injections shift to a stable monthly maintenance schedule.
- 1×/month: New frequency (placeholder metric)
- Fixed effective: Dose (placeholder metric)
- 3–5 yr: Typical length (placeholder metric)
- Sustained exposure: Goal (placeholder metric)
Holding the effective dose
Steady monthly dosing maintains immune exposure long term.
Immunologic Tolerance Development
Regulatory T-cell shifts gradually reduce allergic sensitivity.
- Treg induction: Key mechanism (placeholder metric)
- IgG4 rise: Antibody shift (placeholder metric)
- Months–years: Onset (placeholder metric)
- Long-lasting: Durability (placeholder metric)
How tolerance builds
Repeated exposure retrains immune tolerance pathways over time.
Multi-Year Course Completion Benefit
Completing 3–5 years offers benefit lasting after stopping.
- 3–5 yr: Recommended course (placeholder metric)
- Years: Post-course benefit (placeholder metric)
- Substantial: Symptom relief (placeholder metric)
- Lower: Relapse risk (placeholder metric)
Why full-course completion matters
Stopping early risks losing durable tolerance benefits.
Full-course adherence is placeholder key takeaway text.